Biological distribution of 131I-HAb18F(ab')2 in patients with hepatocellular carcinoma.
- Author:
Wusheng LU
1
;
Xiao LI
;
Chaohua WANG
;
Wenxiu LIU
;
He JIAO
;
Tingshu MO
;
Zhinan CHEN
Author Information
1. Radiologic Department of West China Hospital, Sichuan University, Chengdu 610041.
- Publication Type:Clinical Trial
- MeSH:
Adult;
Aged;
Antibodies, Monoclonal;
administration & dosage;
pharmacokinetics;
Carcinoma, Hepatocellular;
radiotherapy;
Female;
Humans;
Immunoglobulin Fab Fragments;
administration & dosage;
metabolism;
Iodine Radioisotopes;
administration & dosage;
pharmacokinetics;
Liver Neoplasms;
radiotherapy;
Male;
Middle Aged;
Radioimmunotherapy;
Radiopharmaceuticals;
administration & dosage;
pharmacokinetics;
Tissue Distribution
- From:
Journal of Biomedical Engineering
2003;20(4):689-691
- CountryChina
- Language:Chinese
-
Abstract:
Before 131I-HAb18F(ab')2 administration, 24 cases of mid-term or advanced hepatocellular carcinoma(HCC) were given Lugol's Liquid to block the thyroid gland, and submitted to hepatic colloid imaging. The cases were randomly divided into 3 groups. Then 131I-HAb18F(ab')2 was injected into the target hepatic artery with doses of 0.5, 0.75, 1.0 mCi/kg, respectively. At the followed 10, 48, 96 and 192 hours, 131I-HAb18F(ab')2 distribution in human body was acquired by whole body dynamic image with Single photon emission computed tomography(SPECT). The results showsed that 131I-HAb18F(ab')2 in tumor tissue was significantly higher than that in normal liver tissue and other organs. This difference became obvious as time passed. 131I-HAb18F(ab')2 is stable in human body and it can combine with HCC tissue specifically. So it is a new medicine deserving further research for the treatment of HCC.
